3-year outcomes of men on AS in US community urology settings

To date we have seen very few data on the long-term follow-up of men in the US being initially managed on active surveillance (AS) after diagnosis with prostate cancer out in the “real world” of community urology practice. … READ MORE …

Patient satisfaction and the management of localized prostate cancer

A recent paper from a large Swedish research group has addressed patient satisfaction and the management of localized prostate cancer — with a specific, inclusive focus on the satisfaction of men initially managed on active surveillance. … READ MORE …

Updated results of 5-year SBRT trial: high cancer control, low toxicity

Meier et al. have just published updated results of a 5-year multi-institutional trial finding that stereotactic body radiation therapy (SBRT) had high rates of cancer control and low toxicity. … READ MORE …

Active surveillance in men with Gleason 3 + 4 = 7 prostate cancer at diagnosis

A critical question for men with favorable intermediate-risk prostate cancer (based primarily on a Gleason score of 3 + 4 = 7) can often be, “How safe would it be for me to go on active surveillance for a while after initial diagnosis?” … READ MORE …

Is Retzius-sparing radical prostatectomy the surgical wave of the future?

Back in the early 1980s, Dr. Patrick Walsh at the Johns Hopkins Medical Center in Baltimore changed the nature of surgical treatment for prostate cancer when he first started to conduct so-called nerve-sparing radical prostatectomies. … READ MORE …

Updated PIVOT data seem to support recent AUA/ASTRO/SUO guidelines

A new article in this week’s New England Journal of Medicine has given us follow-up data from the PIVOT trial of radical prostatectomy vs. simple observation in treatment of localized prostate cancer. … READ MORE …

Eighth randomized clinical trial of hypofractionated radiation therapy

We now have data from an eighth randomized clinical trial of hypofractionated radiation therapy. There are no surprises: … READ MORE …

Letters to the Editor on interpretation of data from the ProtecT trial

In September last year, Hamdy et al. published the initial results of the ProtecT trial — a trial designed to compare overall outcomes at 10 years among > 1,600 men diagnosed with low- and intermediate-risk, localized prostate cancer and randomized to treatment by surgery, by external beam radiation therapy, or by active monitoring (a very basic form of active surveillance). … READ MORE …

Early chemotherapy in treatment of high-risk and aggressive prostate cancers?

So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …

Body mass index, surgery, and risk for prostate cancer-specific death

It is well understood that there is an association between obesity and future risk for prostate cancer-specific mortality among cancer-free men. What has not been so clear is the relationship between obesity and long-term outcomes, post-treatment, among men diagnosed early with localized disease … READ MORE …

Hypofractionated radiation therapy using IMRT has a clear advantage

I was reticent to write about hypofractionation yet again after writing about it so often in the last year (see this link for my latest summary). … READ MORE …

Patient-reported outcomes and quality of life in the ProtecT trial

We have already commented on the oncologic outcomes of patients enrolled in the ProtecT trial and published in today’s issue of the New England Journal of Medicine. In this commentary we shall comment on the separate paper that addresses patient-reported outcomes from that trial. … READ MORE …

Can a man be too young for active surveillance?

There is a “conventional wisdom” that active surveillance (AS) is only for older men, and that younger men are better off having immediate radical treatment, typically prostatectomy (RP).

5-year outcomes after PBRT at a single, high-volume, PBRT center

We have previously reported on the very good, albeit unremarkable, outcomes of proton beam radiation therapy (PBRT) as administered at the University of Florida Jacksonville. … READ MORE …

Data from a Phase II trial of ARN-509 (apalutamide) and more

A report posted on line in European Urology has provided us with important clinical data related to the potential of this investigational drug in the treatment of advanced prostate cancer. … READ MORE …